EZ Cap™ Mouse CD80 mRNA (m1Ψ, HA tag)

CD80 is an important immunomodulatory molecule, a member of the B7 family, expressed primarily on the surface of antigen-presenting cells such as dendritic cells, B cells, and activated T cells. CD80 regulates the activation and inhibition of T cells by binding to CD28 and CTLA-4 receptors on the surface of T cells, and the binding to CD28 promotes the activation and proliferation of T cells, thereby enhancing the immune response, while the binding to CTLA-4 plays an inhibitory role, helping to maintain immune tolerance and prevent excessive immune response. The expression and function of CD80 are important in a variety of immune-related diseases and have been the target of many immunotherapy strategies, such as autoimmune diseases, transplant rejection, and cancer immunity.

EZ Cap™ Mouse CD80 mRNA (m1Ψ, HA tag) is provided at a concentration of ~1 mg/ml with Cap1 structure. It expresses Mouse CD80 cytokine with HA label, which is convenient for the subsequent detection of protein expression. There are currently two ways to cap mRNA: One is co-transcription method, by adding Cap analogues into the transcription process. The other is enzymatic Capping. After transcription, Cap0 capping is performed by Vaccinia virus Capping Enzyme (VCE), GTP and S-adenosylmethionine (SAM). The Cap0 is then generated into the Cap1 through 2´-O-Methyltransferase and SAM. Cap1 Capping can also be performed by adding VCE, 2´-O-Methyltransferase, GTP and SAM in a one-step process. Cap 1 structure is more ideal for mammalian systems and possess higher transcription efficiency than Cap 0 structure. The addition of N1-Methylpseudo-UTP(m1Ψ) and poly(A) tail suppress RNA-mediated innate immune activation and increase the stability and lifetime of the mRNA in vitro and in vivo. Poly(A) tail also plays an important role in enhancing the efficiency of translation initiation.